Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy. Based on different patterns of disease progression, patients will receive relevant systemic treatments, either with or without local interventional therapy. The primary endpoint is progression-free survival (PFS), while secondary endpoints include overall survival (OS), 1-year OS rate, objective response rate (ORR), disease control rate (DCR), duration of remission (DOR), and safety. Additionally, the study will explore the correlation between patients' clinical pathological characteristics, serum biomarkers, and clinical efficacy.

NCT Number	NCT06893887
Lead Sponsor	Nanjing Tianyinshan Hospital
Conditions	Hepatocellular Carcinoma(HCC)
Enrollment	300 participants
Start Date	2025-05-22
Primary Completion	2027-03-15 (estimated)
Study Completion	2028-03-15 (estimated)
Updated on ClinicalTrials.gov	2025-07-02